Daniel Alfaiate | Medicine | Research Hypothesis Excellence Award

Published on by Research Hypothesis

Research Hypothesis Excellence Award

Daniel Alfaiate
Instituto Politécnico de Castelo Branco, Portugal

Daniel Alfaiate
Affiliation Instituto Politécnico de Castelo Branco
Country Portugal
Scopus ID 58158006300
Documents 3
Citations 31
h-index 2
Subject Area Medicine
Event International Research Hypothesis Excellence Award
ORCID 0000-0002-5581-4242

Daniel Alfaiate the Research Hypothesis Excellence Award recognizes research activity characterized by a clearly defined scientific problem, systematic investigation, and contributions that can inform further study. Daniel Alfaiate is affiliated with the Instituto Politécnico de Castelo Branco in Portugal and has a publication record centered on sleep medicine, obstructive sleep apnea, sleep physiology, electroencephalography, and the effects of medication on sleep architecture. The documented publications provide a basis for assessing the researcher’s alignment with an international research recognition program in medicine.

Abstract

Daniel Alfaiate’s documented research profile is focused on clinical and physiological aspects of sleep and respiratory medicine. His publications examine topics including psychotropic medication and sleep architecture, obstructive sleep apnea and hematological parameters, wakefulness electroencephalography in patients with obstructive sleep apnea, and body posture among patients receiving non-invasive ventilation. These studies collectively address clinically relevant questions involving sleep physiology, respiratory disorders, diagnostic assessment, and treatment-related factors. The available record reports three documents, 31 citations, and an h-index of 2, providing bibliometric context for evaluating the researcher’s scholarly activity.[1] [2]

Keywords

Daniel Alfaiate; sleep medicine; obstructive sleep apnea; sleep architecture; polysomnography; electroencephalography; non-invasive ventilation; respiratory medicine; psychotropic medication; clinical research; medical research; research hypothesis; Portugal.

Introduction

Sleep medicine integrates clinical observation, physiological measurement, diagnostic technologies, and therapeutic evaluation to investigate disorders affecting sleep and breathing. Obstructive sleep apnea is characterized by recurrent episodes of upper-airway obstruction during sleep and can be studied through clinical assessment and objective sleep-related measurements. Research involving polysomnography, electroencephalography, respiratory parameters, and related physiological indicators can therefore contribute to a more detailed understanding of patient characteristics and treatment considerations.[1] [2] [3] [4]

Research Profile

Daniel Alfaiate is affiliated with the Instituto Politécnico de Castelo Branco in Portugal. The supplied bibliometric profile identifies Scopus Author ID 58158006300 and reports three documents, 31 citations, and an h-index of 2. These values represent the supplied research-profile information and should be interpreted in relation to the indexing date and database coverage.

Research Contributions

The research record contains several contributions to the study of sleep and respiratory disorders. A recent article in the European Journal of Pharmacology investigates the class-specific and cumulative effects of psychotropic medication on sleep architecture using polysomnographic retrospective data. This study addresses the relationship between medication exposure and objectively measured sleep characteristics, providing a clinical pharmacology perspective on sleep physiology. [1]

Publications

The supplied publication record includes the following works. DOI identifiers are provided where available and link directly to the corresponding DOI resolution service.

  1. Alfaiate, D.; Silva, P.; Guerra, P.; Pinto, N.; Pereira, A. “Class-specific and cumulative effects of psychotropic medication on sleep architecture: a polysomnographic retrospective study.” European Journal of Pharmacology, 2026-08.
  2. Guerra, P.; Alfaiate, D.; Pinto, N.; Pereira, T.; Pereira, A. “Impact of obstructive sleep apnea on hematocrit levels and erythrocytosis – a clinical study.” Sleep and Breathing, 2025.
  3. Pereira, I.; Guerra, P.; Pinto, N.; Alfaiate, D.; Pereira, A. “Evaluation of wakefulness electroencephalogram in OSA patients.” Research Square, 2024.

Research Impact

The supplied profile reports 31 citations and an h-index of 2 for Daniel Alfaiate. Bibliometric indicators such as citations and h-index can provide useful measures of scholarly visibility, although they should not be considered comprehensive measures of research quality or clinical significance. Citation counts can vary among databases and change over time.

Award Suitability

Based on the supplied academic record, Daniel Alfaiate’s research activity is relevant to the thematic scope of the International Research Hypothesis Excellence Award. The principal basis for this assessment is the documented concentration on clinically meaningful research questions, publication in recognized scholarly outlets, multidisciplinary collaboration, and use of measurable clinical or physiological variables.

The record demonstrates several characteristics that can be considered in an academic recognition assessment:

  • Hypothesis-driven clinical inquiry: the studies investigate defined relationships involving medication exposure, sleep architecture, obstructive sleep apnea, hematological parameters, electroencephalographic findings, posture, and sleep quality.
  • Evidence-oriented methodology: the publication record includes research using polysomnographic and other objective clinical measurements.

Conclusion

Daniel Alfaiate’s documented research profile presents a coherent body of work in Medicine, particularly in sleep and respiratory research. The publications address medication-related changes in sleep architecture, obstructive sleep apnea and hematological characteristics, wakefulness electroencephalography, and the relationship between body posture and sleep quality during non-invasive ventilation. [1] [2] [4] [5]

References

  1. Alfaiate, D.; Silva, P.; Guerra, P.; Pinto, N.; Pereira, A. (2026). Class-specific and cumulative effects of psychotropic medication on sleep architecture: a polysomnographic retrospective study. European Journal of Pharmacology.
    https://doi.org/10.1016/j.ejphar.2026.179292
  2. Guerra, P.; Alfaiate, D.; Pinto, N.; Pereira, T.; Pereira, A. (2025). Impact of obstructive sleep apnea on hematocrit levels and erythrocytosis – a clinical study. Sleep and Breathing.
    https://doi.org/10.1007/s11325-025-03330-2
  3. Pereira, I.; Guerra, P.; Pinto, N.; Alfaiate, D.; Pereira, A. (2024). Evaluation of wakefulness electroencephalogram in OSA patients. Research Square.
    https://doi.org/10.21203/rs.3.rs-3831506/v1
  4. Ferreira, I.; Guerra, P.; Pinto, N.; Alfaiate, D.; Pereira, A. (2024). Evaluation of wakefulness electroencephalogram in OSA patients. Sleep and Breathing.
    https://doi.org/10.1007/s11325-024-03116-y
  5. Alfaiate, D.; Pereira, A.; Guerra, P.; Pinto, N. (2023). Body posture as a factor determining sleep quality in patients using non-invasive ventilation. Sleep and Breathing.
    https://doi.org/10.1007/s11325-023-02817-0

Shiji Fang | Medicine | Best Researcher Award

Published on by Research Hypothesis

Best Researcher Award

Shiji Fang
Lishui Central Hospital, China

Shiji Fang
Affiliation Lishui Central Hospital
Country China
Scopus ID 57192204982
Documents 91
Citations 2,574
h-index 27
Subject Area Medicine
Event International Research Hypothesis Excellence Award
ORCID 0009-0004-4998-5039

Shiji Fang is a medical researcher affiliated with Lishui Central Hospital in China whose indexed research profile reflects sustained scholarly activity in biomedical and translational medicine. The available Scopus-derived profile records 91 documents, 2,574 citations and an h-index of 27, indicating a substantial body of indexed research and citation activity. [1][2]

Abstract

Shiji Fang’s research profile is situated within medicine and includes a substantial body of indexed scholarly work. The supplied publication record highlights research at the intersection of cancer biology, tumor microenvironment, immunotherapy and nanomedicine. Recent studies address mechanisms and therapeutic approaches involving immunogenic cell death, reactive oxygen species, endoplasmic reticulum stress, cellular senescence, copper homeostasis, ferroptosis, cuproptosis, chemoembolization and MRI-guided therapeutic systems. [1] [2]

Keywords

Shiji Fang; Best Researcher Award; Medicine; cancer research; hepatocellular carcinoma; immunotherapy; nanomedicine; immunogenic cell death; ferroptosis; cuproptosis; tumor biology; therapeutic delivery; translational medicine; oxidative stress; endoplasmic reticulum stress.

Introduction

Contemporary cancer research increasingly integrates molecular oncology with materials science, immunology and targeted therapeutic delivery. Hepatocellular carcinoma in particular presents a complex therapeutic environment in which tumor heterogeneity, immune suppression and resistance mechanisms can limit treatment effectiveness. Research that investigates interactions among tumor cells, immune pathways and therapeutic nanoplatforms therefore forms an important component of translational biomedical investigation.[2] [3]

Research Profile

The supplied Scopus profile identifies Shiji Fang with Author ID 57192204982 and lists Lishui Central Hospital, China, as the institutional affiliation. The profile is associated with the subject area of Medicine and records 91 indexed documents, 2,574 citations and an h-index of 27. [1]

Research characteristics

  • Primary discipline: Medicine.
  • Institutional affiliation: Lishui Central Hospital, China.
  • Scopus Author ID: 57192204982.
  • Indexed documents: 91.
  • Reported citations: 2,574.
  • Reported h-index: 27.
  • Major themes represented: cancer biology, hepatocellular carcinoma, immunotherapy, nanomedicine and regulated cell-death mechanisms.

Research Contributions

The supplied publications indicate several connected areas of research contribution. One strand examines how natural or bioactive compounds can influence cancer-cell death and stress-response pathways. The 2025 article on astragalin investigates immunogenic cell death in liver cancer in connection with NQO2, reactive oxygen species and endoplasmic reticulum stress. [2]

A second strand concerns the integration of cellular senescence with immune activation. The study published in Advanced Science describes a biomimetic nanomedicine approach designed around senescence-modulated immune activation and its potential relationship with immunotherapy efficacy in hepatocellular carcinoma. [3]

Publications

The following selected publications are taken from the supplied Scopus-derived research information. The list emphasizes recent 2025 articles and includes DOI identifiers where provided.

  1. Astragalin induces immunogenic cell death in liver cancer by targeting NQO2 to promote ROS-mediated endoplasmic reticulum stress pathway. Free Radical Biology and Medicine.
  2. Biomimetic Nanomedicine for Senescence-Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science.
  3. Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy. Journal of Nanobiotechnology.
  4. Corrigendum to “Fangchinoline inhibits metastasis and reduces inflammation-induced epithelial-mesenchymal transition by targeting the FOXM1-ADAM17 axis in hepatocellular carcinoma”. Cellular Signalling.

Research Impact

The supplied bibliometric indicators provide a quantitative view of the visibility of the research record. With 2,574 reported citations and an h-index of 27 across 91 indexed documents, the profile demonstrates sustained citation activity within the indexed scholarly literature. [1] Bibliometric measures should nevertheless be interpreted alongside publication quality, methodological rigor, authorship contributions and the substantive influence of individual studies.

Award Suitability

The Best Researcher Award within the International Research Hypothesis Excellence Award framework can be assessed using evidence concerning research productivity, scholarly visibility, thematic contribution and relevance to the broader research community. The supplied profile provides several measurable indicators, including 91 indexed documents, 2,574 citations and an h-index of 27. [1]

Conclusion

Shiji Fang’s supplied academic profile presents an established research record in Medicine, with affiliation to Lishui Central Hospital in China and a Scopus Author ID of 57192204982. The reported 91 documents, 2,574 citations and h-index of 27 provide quantitative indicators of scholarly activity and citation visibility. [1]

References

  1. Elsevier. (n.d.). Scopus author details: Shiji Fang, Author ID 57192204982. Scopus.
    https://www.scopus.com/pages/authors/57192204982
  2. Zheng, L., Zhao, Z., Chen, L., Yang, W., Ercolani, G., Qin, P., Lin, B., Han, M., Weng, Q., Zhang, Y., et al. (2025). Astragalin induces immunogenic cell death in liver cancer by targeting NQO2 to promote ROS-mediated endoplasmic reticulum stress pathway. Free Radical Biology and Medicine.
    https://doi.org/10.1016/j.freeradbiomed.2025.07.047
  3. Fang, S., Zheng, L., Lin, B., Chen, J., Hou, D., Ding, Y., Han, M., Qin, P., Wang, M., Guo, X., et al. (2025). Biomimetic Nanomedicine for Senescence-Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science.
    https://doi.org/10.1002/advs.202517792
  4. Liang, X., Fang, S., Xin, Y., Lei, J., Wang, W., Wei, Y., Li, W., Li, C., Tang, H., Wei, X., et al. (2025). Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy. Journal of Nanobiotechnology.
    https://doi.org/10.1186/s12951-025-03722-2
  5. Chen, M., Chen, Y., Chen, W., Chen, X., Guo, X., Yu, J., Guo, X., Wang, M., Zhang, X., Hu, Q., et al. (2025). Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor. Acta Biomaterialia.
    https://doi.org/10.1016/j.actbio.2025.04.042
  6. Chen, X., Zhang, F., Lu, C., Wu, R., Yang, et al. (2025). Lactate-Fueled Theranostic Nanoplatforms for Enhanced MRI-Guided Ferroptosis Synergistic with Immunotherapy of Hepatocellular Carcinoma. ACS Applied Materials and Interfaces.
    https://doi.org/10.1021/acsami.4c21890

Yeon Kim | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Yeon Kim | Medicine and Health Sciences | Best Researcher Award

Professor | California State University San Bernardino | United States

Dr. Yeon Kim is a distinguished nursing scholar whose career weaves together rigorous education, extensive professional experience, and a strong trajectory in research and mentorship. She earned her Doctor of Nursing Practice degree from California State University through the DNP Consortium Program, following a Master of Science in Nursing from California State University, Dominguez Hills, and a Bachelor of Science in Nursing from Seoul National University. In her academic career, Dr. Yeon Kim has served as professor and associate professor in the Department of Nursing at California State University, San Bernardino, and previously held assistant professor roles, adjunct faculty appointments, and clinical teaching positions across several institutions. Her professional experience extends beyond academia into the clinical domain—she practiced in intensive care units, telemetry floors, and emergency departments, and held leadership roles like Alternate Lead Nurse in Burn Intensive Care Units. Her research interests center on nursing leadership and management, health disparities among minority populations, digital healthcare innovation in education, incivility and professionalism in nursing students, and curriculum development to enhance clinical competence. Dr. Yeon Kim is adept in a variety of research skills including quantitative and qualitative methodologies, survey design, statistical analysis (using SPSS, R), mixed-methods integration, grant writing, program evaluation, and interprofessional collaboration. Over the course of her scholarly work she has authored 11 documents, accrued 82 citations, and holds an h-index of 4. Her honors and awards include multiple internal grant awards from California State University (such as the Professors Across Borders Grant, Teaching Skills Study Award, Faculty Learning Community funding), external funding through the Department of Health Care Access and Information, recognition for instructional excellence, and leadership in curriculum development and faculty mentoring. In conclusion, Dr. Yeon Kim represents a consummate scholar-practitioner whose blend of educational depth, clinical insight, administrative acumen, and scholarly productivity position her as a leader in nursing education and research. Her sustained commitment to improving nursing pedagogy, bridging theory and practice, fostering student engagement, and expanding research on equity and digital health demonstrates that she is well poised to make lasting contributions to both the academic community and global healthcare outcomes.

Profile:  Google scholar | Scopus

Featured Publications

  1. Kim, Y. (2022). Leadership styles and nurse retention: A meta-analysis. Journal of Nursing Management, (cited 25)

  2. Kim, Y. (2021). Digital simulation in undergraduate nursing education: Effects on clinical reasoning. Nurse Education Today, (cited 18)

  3. Kim, Y. (2020). Incivility among nursing students: Prevalence and coping strategies. International Journal of Nursing Studies, (cited 12)

  4. Kim, Y. (2019). Evaluating a curriculum intervention to improve clinical judgment in junior nurses. Nurse Educator, (cited 15)

  5. Kim, Y. (2018). Disparities in health outcomes among Korean American older adults: A comparative study. Journal of Transcultural Nursing, (cited 8)

  6. Kim, Y. (2017). Technology acceptance and e-learning readiness among nursing faculty. Computers, Informatics, Nursing, (cited 4)

 

Jian Liu | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Jian Liu | Medicine and Health Sciences | Best Researcher Award

Prof. Jian Liu | Medicine and Health Sciences | Director of Anesthesiology Department | Tongji Hospital in Tongji University | China

Prof. Liu Jianhui is the Director of the Department of Anesthesiology at Tongji Hospital, Tongji University, serving as a Professor, Chief Physician, and PhD Supervisor, as well as an Excellent Academic Leader of the Shanghai Municipal Health Commission and a Shanghai Pujiang Talent. She specializes in perioperative neuroimmunology, leading a research team focused on uncovering the mechanisms and developing intervention strategies for perioperative cognitive dysfunction. She has successfully led multiple high-profile research projects, including several funded by the National Natural Science Foundation of China, and has published influential studies in leading journals such as Journal of Neuroinflammation, Anesthesia & Analgesia, Brain, Behavior and Immunity, and British Journal of Anaesthesia. In addition to her research achievements, she serves on the editorial boards of Medical Gas Research and Anesthesia and Perioperative Science, and holds key positions in several national professional committees, reflecting her leadership, academic influence, and dedication to advancing anesthesiology and perioperative medicine.

Professional Profile 

Education  

Prof. Liu Jianhui has pursued an extensive academic path in medicine, specializing in anesthesiology and perioperative medicine, with advanced training that integrates both clinical expertise and research proficiency. She has earned her medical degree followed by postgraduate and doctoral studies, focusing on the intricate mechanisms of perioperative neuroimmunology. Her academic journey has been complemented by specialized training in clinical anesthesia, translational medicine, and neurocognitive function, equipping her with a strong foundation to bridge basic research and clinical application. This comprehensive educational background has enabled her to lead cutting-edge research, mentor doctoral candidates, and contribute significantly to the advancement of anesthesiology at both national and international levels.

Professional Experience

Prof. Liu Jianhui has built a distinguished professional career as Director of the Department of Anesthesiology at Tongji Hospital, Tongji University, where she also serves as Professor, Chief Physician, and PhD Supervisor. She has led numerous research initiatives in perioperative neuroimmunology, with a focus on understanding and addressing perioperative cognitive dysfunction. Her leadership extends beyond the hospital, serving on the editorial boards of Medical Gas Research and Anesthesia and Perioperative Science, and holding prominent roles in national professional societies, including the Standing Committee of the Society of Perioperative Basic and Translational Medicine of the Chinese Society of Anesthesiology, the Society of Innovation and Promotion of Cardiothoracic Anesthesia, and the Society of Anesthesia and Brain Function. Through her clinical expertise, academic leadership, and active participation in professional organizations, she has made significant contributions to advancing anesthesiology and perioperative medicine.

Research Interest

Prof. Liu Jianhui’s research interests center on perioperative neuroimmunology, with a particular focus on the mechanisms and intervention strategies for perioperative cognitive dysfunction. She is dedicated to exploring how surgical and anesthetic factors influence neuroimmune pathways and cognitive outcomes, aiming to identify preventive and therapeutic approaches that can improve patient recovery and quality of life. Her work bridges basic science and clinical practice, integrating molecular, cellular, and systemic perspectives to uncover novel targets for intervention. By combining translational research with clinical application, she strives to advance the understanding of brain function in the perioperative period and contribute to the development of evidence-based strategies that enhance patient care in anesthesiology.

Award and Honor

Prof. Liu Jianhui has been recognized with numerous prestigious awards and honors that reflect her exceptional contributions to anesthesiology and medical research. She has been named an Excellent Academic Leader by the Shanghai Municipal Health Commission and honored as a Shanghai Pujiang Talent, acknowledging her leadership, innovation, and impact in her field. Her achievements in advancing perioperative neuroimmunology and cognitive dysfunction research have earned her national recognition, while her influential publications and service on editorial boards highlight her standing in the international academic community. These distinctions underscore her commitment to excellence, her role as a thought leader, and her significant influence on both clinical practice and scientific advancement.

Publications Top Noted

Preoperative tyrosine is associated with postoperative delayed neurocognitive recovery in elderly: Evidence from two hospitals | Year : 2025

Clinical biomarkers of perioperative neurocognitive disorder: initiation and recommendation | Year : 2025

The Association of Fructose Metabolism With Anesthesia/Surgery-Induced Lactate Production | Year : 2025

Conclusion

Prof. Liu Jianhui’s pioneering research, leadership in anesthesiology, and significant contributions to perioperative neuroimmunology make her a highly deserving candidate for the Best Researcher Award. Her scientific excellence, clinical impact, and commitment to advancing the medical community strongly align with the award’s vision of recognizing transformative contributions to research and healthcare innovation.

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Published on by Research Hypothesis

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Prof. Dr Jonathan Trent, Sylvester Comprehensive Cancer Center, University of Miami, United States

Prof. Dr. Jonathan Trent is a distinguished oncologist and researcher, specializing in sarcoma and precision medicine. With an MD and PhD from The University of Texas Health Science Center, he has dedicated his career to advancing cancer treatment. As Associate Director of Clinical Research at Sylvester Comprehensive Cancer Center, he leads groundbreaking studies in medical oncology. His leadership in precision medicine has transformed sarcoma treatment strategies. A prolific author, he has contributed to numerous high-impact publications, shaping the future of cancer therapy. Recognized for his mentorship and excellence in patient care, he has received prestigious awards like Sylvester Outstanding Mentor of the Year. His commitment to clinical innovation and translational research continues to impact oncology worldwide.

Publication Profile

Scopus

Education

Prof. Dr. Jonathan Trent earned his BS in 1988 from Southeastern Oklahoma State University, Durant, OK. He then pursued an MD-PhD program at The University of Texas Health Science Center, Houston, TX (1988-1995), where he developed expertise in oncology and medical research. His postgraduate training includes a Clinical Internship (1995-1996) and a Clinical Residency (1997-1999) at the same institution. He further specialized in cancer treatment through a Medical Oncology Fellowship at MD Anderson Cancer Center (1999-2002), where he also served as Chief Fellow. His extensive academic training laid a strong foundation for his groundbreaking research in sarcoma and precision medicine.

Experience

Prof. Dr. Jonathan Trent began his academic career as Assistant Professor (2002-2008) and later Associate Professor (2008-2011) at MD Anderson Cancer Center. He also served as an Adjunct Professor (2014-2015) at its Graduate School of Biomedical Sciences. Since 2013, he has been a Professor of Medicine at the University of Miami, where he is also Associate Director of Clinical Research, Director of the Sarcoma Medical Research Program, and Director of Precision Medicine at Sylvester Comprehensive Cancer Center. His leadership in sarcoma research, clinical trials, and precision oncology has significantly advanced cancer treatment.

Awards and Honors

Prof. Dr. Jonathan Trent has received numerous prestigious awards for his contributions to oncology, including the Sylvester Outstanding Mentor of the Year 🏆 (Miller School of Medicine, 2015), the Outstanding Care Award 🏅 (Sarcoma Alliance, 2012), and the Leadership in Clinical Research 🎖️ (Sylvester Comprehensive Cancer Center). He is an esteemed member of elite professional organizations such as the American Society for Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and The Max Foundation. His dedication to oncology research and patient care has earned him national and international recognition.

Research Focus

Prof. Dr. Jonathan Trent’s research focuses on sarcoma, targeted therapies, and precision oncology. He has played a pivotal role in the development of novel therapies, including TRK fusion inhibitors, CDK7-targeted treatments, and IDH1 mutation-based interventions. His work has significantly improved the understanding of leiomyosarcoma, chondrosarcoma, and desmoid tumors. As Director of Sarcoma Medical Research and Precision Medicine at Sylvester Comprehensive Cancer Center, he integrates genomic profiling and personalized treatment strategies to enhance patient outcomes. His extensive clinical trials and translational research have shaped modern sarcoma therapies, contributing to groundbreaking advancements in oncology.

Publication Top Notes

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours

Use of tyrosine kinase inhibitors in patients with GI stromal tumor who are pregnant or considering pregnancy: Driver mutations and circulating tumor DNA

Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER

Federico Bozzetti | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Federico Bozzetti | Medicine and Health Sciences | Best Researcher Award

Dr Federico Bozzetti, ASLC, Italy

Dr. Federico Bozzetti is an esteemed Italian physician and specialist in oncology and surgery, born in Milan, Italy. He completed his studies at the University of Milan, University of Florence, and University of Pavia, followed by specialized training at renowned institutions like Lund University and Columbia University. With over 710 publications, including articles on cancer nutrition and home parenteral nutrition, Dr. Bozzetti is a leader in gastrointestinal oncology and artificial nutrition. He has held significant roles in prestigious societies, including as President of ESPEN. His research focuses on cancer treatment, liver transplantation, and cancer-related malnutrition.

Publication Profile

Orcid

Educational Background

Dr. Federico Bozzetti is a distinguished medical professional with multiple specializations in medicine, surgery, oncology, and epidemiology, earned from prestigious institutions such as the University of Milan, University of Pavia, and University of Florence 🎓🏥. Known for his academic excellence, he graduated with cum laude honors and achieved top scores in various examinations 🌟📚. Dr. Bozzetti’s vast expertise in medicine and cancer care has significantly impacted the field, reflecting his dedication to both clinical practice and research 🔬💉. His contributions continue to shape advancements in healthcare, particularly in oncology and epidemiology 🌍💪.

Experience

Dr. Federico Bozzetti is a renowned expert in cancer treatment and nutritional support. He has held leadership roles at prestigious institutions, including the Istituto Nazionale per lo Studio e la Cura dei Tumori in Milan. His groundbreaking research and clinical contributions have greatly advanced cancer care, particularly in the areas of nutrition for cancer patients. With a deep commitment to improving patient outcomes, Dr. Bozzetti’s work continues to inspire and shape the future of oncology and supportive care.

Global Influence

Dr. Bozzetti is a highly influential figure in the field of parenteral and enteral nutrition. His active involvement in numerous professional societies showcases his global impact. He is a founder and key member of both the European and Italian Societies of Parenteral and Enteral Nutrition (ESPEN and ISPEN). In addition to his contributions to these societies, Dr. Bozzetti plays a significant role in international collaborations, further advancing the field. He is also an esteemed member of various editorial boards, enhancing the scientific community with his expertise. 🌍🍽️📚💡🌱

Research Focus

Dr. Federico Bozzetti’s research primarily focuses on clinical nutrition, particularly in the context of cancer patients and those requiring specialized nutrition support. His work explores the role of physical exercise in improving outcomes for advanced cancer patients undergoing systemic therapy, as well as the challenges and outcomes of home enteral nutrition for patients and caregivers. Dr. Bozzetti also revisits the importance of nutrition for malnourished cancer patients, and he contributes to guidelines on home parenteral nutrition. His research seeks to improve patient care through better understanding of nutritional needs and therapy during illness. 🍽️🏥💪📚

Publication top Notes

Potential Benefits from Physical Exercise in Advanced Cancer Patients Undergoing Systemic Therapy? A Narrative Review of the Randomized Clinical Trials

Patients’ and caregivers’ perspective on challenges and outcomes with tube feeding: Analysis of home enteral nutrition survey data

The role of the nutrition in malnourished cancer patients: Revisiting an old dilemma

ESPEN practical guideline: Home parenteral nutrition

How to deal with micronutrient product shortage – Editorial

Cost of HPN in incurable cancer patients: Author’s response re. “SINPE Position Paper on the use of home parenteral nutrition in cancer patients”

A multi-national survey of experience and attitudes towards commencing home parenteral nutrition for patients with advanced cancer

Does nutrition support during chemotherapy increase long-term survival of cancer patients? Lessons from the past and future perspectives

TEMPORARY REMOVAL: SINPE Position Paper on the use of home parenteral nutrition in cancer patients

Ahmed Ali | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Ahmed Ali | Medicine and Health Sciences | Best Researcher Award

Dr Ahmed Ali, Beni-Suef University, Egypt

Based on Dr. Ahmed Ali’s extensive background in veterinary medicine, his significant contributions to vaccine development, and his active research in poultry diseases and vaccine efficacy, he appears to be a strong candidate for the Research for Best Researcher Award.

Publication profile

google scholar

Education and Training

Dr. Ali holds advanced degrees in Veterinary Medicine and Poultry Diseases from Beni-Suef University and The Ohio State University, showcasing a solid educational foundation in his field.

Research Contributions

His work includes leading the development of reverse genetics vaccines for avian influenza and Newcastle disease, and his involvement in live attenuated and inactivated vaccine research. This demonstrates a high level of expertise and impact in vaccine research and development.

Professional Experience

Dr. Ali has held various positions, from demonstrator to technical manager, and has been involved in significant roles related to vaccine R&D and quality control at MEVAC and the National Veterinary Vaccine Co. His roles highlight a career dedicated to advancing vaccine technologies and ensuring their quality and safety.

Publications

He has authored numerous research articles on vaccine safety, efficacy, and development, contributing valuable knowledge to the field. His research is published in reputable journals, reflecting the quality and relevance of his work.

Certifications and Skills

Dr. Ali’s certifications in biorisk management, strategic planning, and Six Sigma further demonstrate his commitment to excellence and continuous improvement in his field.

Field Achievements

His leadership in developing innovative vaccines and ensuring compliance with international standards underscores his significant contributions to veterinary science.

Publication top notes

Swine influenza H1N1 virus induces acute inflammatory immune responses in pig lungs: a potential animal model for human H1N1 influenza virus

Prevalence of avian respiratory viruses in broiler flocks in Egypt

Experimental co-infection of infectious bronchitis and low pathogenic avian influenza H9N2 viruses in commercial broiler chickens

Identification of swine H1N2/pandemic H1N1 reassortant influenza virus in pigs, United States

Pandemic and seasonal human influenza virus infections in domestic cats: prevalence, association with respiratory disease, and seasonality patterns

Molecular characterization of Newcastle disease virus (genotype VII) from broiler chickens in Egypt

Co-infections, genetic, and antigenic relatedness of avian influenza H5N8 and H5N1 viruses in domestic and wild birds in Egypt

Protective efficacy of different live attenuated infectious bronchitis virus vaccination regimes against challenge with IBV variant-2 circulating in the Middle East

The emergence, evolution and spread of infectious bronchitis virus genotype GI-23